Project
A retrospective, Swiss multi-center study to investigate the efficacy of natalizumab in second line therapy
Completed ยท 2008 until 2009
Putzki Norman
Type
Range
Units
Status
Start Date
End Date
Financing
Study Design
Keywords
Partner
Additional Information
Brief description/objective
Natalizumab is restricted to patients with treatment failure to IFN-beta and to highly active MS. The pivotal trials were not designed to examine this scenario. This study seeks to add at least 100 patient years experience in second line therapy of RRMS.